Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...
Click to read the study in the European Journal of Cancer.
1. Adding sargramostim to ipilimumab for advanced melanoma resulted in improvement in overall survival and fewer adverse events when compared ...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.